The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer

Por Cho, Byoung Chul, Kim, Joo Hang, Soo, Ross A, Yang, Chih-Hsin
Publicado em 2010

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanc...

Por Pereira, José Rodrigues, Cheng, Rebecca, Orlando, Mauro, Kim, Joo-Hang, Barraclough, Helen
Publicado em 2013

Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors

Por Chang, Hyun, Zhang, Xianglan, Cho, Byoung Chul, Park, Hee Jin, Kim, Joo-Hang
Publicado no Thorac Cancer (2014)

Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation

Por Kim, So Young, Kang, Dongxu, Choi, Hye Jin, Joo, Yeonsoo, Kim, Joo-Hang, Song, Jae J.
Publicado no Oncotarget (2017)

Multi-Disciplinary Treatment of a Rare Pelvic Cavity Ependymoma

Por Hwang, Hye Jin, Sohn, Joo Hyuk, Han, Seung Jin, Kim, Tai Seung, Lee, Youn Soo, Kim, Joo Hang
Publicado em 2007

c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment

Por Song, Jae J., Kim, Joo-Hang, Sun, Bo K., Alcala, Marco A., Bartlett, David L., Lee, Yong J.
Publicado em 2010

Usefulness of Bone Metabolic Markers in the Diagnosis of Bone Metastasis from Lung Cancer

Por Chung, Jae Ho, Park, Moo Suk, Kim, Young Sam, Chang, Joon, Kim, Joo Hang, Kim, Sung Kyu, Kim, Se Kyu
Publicado em 2005

TRAIL-induced caspase/p38 activation is responsible for the increased catalytic and invasive activities of Akt

Por SUN, BO K., KIM, JOO-HANG, NGUYEN, HOAN N., KIM, SO Y., OH, SEEUN, LEE, YONG J., SONG, JAE J.
Publicado em 2011

Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer

Por Kim, Jun Won, Kim, Mi Sun, Kim, Se-Heon, Kim, Joo Hang, Lee, Chang Geol, Kim, Gwi Eon, Keum, Ki Chang
Publicado no Cancer Res Treat (2016)

Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL

Por Huang, Jing-Hua, Zhang, Song-Nan, Choi, Kyung-Ju, Choi, Il-Kyu, Kim, Joo-Hang, Lee, Mingul, Kim, Hoguen, Yun, Chae-Ok
Publicado em 2009

Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients

Por Cho, Byoung Chul, Ahn, Joong Bae, Seong, Jinsil, Roh, Jae Kyung, Kim, Joo Hang, Chung, Hyun Cheol, Sohn, Joo Hyuk, Kim, Nam Kyu
Publicado em 2008

MEKK1/MEKK4 are responsible for TRAIL-induced JNK/p38 phosphorylation

Por Sun, Bo K, Kim, Joo-Hang, Nguyen, Hoan N., Oh, Seeun, Kim, So Y., Choi, Hye J., Lee, Yong J., Song, Jae J.
Publicado em 2010

Prognostic Value of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer

Por Choi, Hye Jin, Kang, Chang Moo, Lee, Woo Jung, Song, Si Young, Cho, Arthur, Yun, Mijin, Lee, Jong Doo, Kim, Joo Hang, Lee, Jae-Hoon
Publicado em 2013

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution

Por Park, Hyung Soon, Lim, Sun Min, Kim, Sora, Kim, Sangwoo, Kim, Hye Ryun, Kwack, KyuBum, Lee, Min Goo, Kim, Joo-Hang, Moon, Yong Wha
Publicado no PLoS One (2016)

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung...

Por Park, Keunchil, Kim, Joo-Hang, Cho, Eun Kyung, Kang, Jin-Hyoung, Shih, Jin-Yuan, Zimmermann, Annamaria Hayden, Lee, Pablo, Alexandris, Ekaterine, Puri, Tarun, Orlando, Mauro
Publicado no Cancer Res Treat (2016)

c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance

Por Song, Jae J., Szczepanski, Miroslaw Jerzy, Kim, So Young, Kim, Joo-Hang, An, Jee Young, Kwon, Yong Tae, Alcala, Marco A., Bartlett, David L., Lee, Yong J.
Publicado em 2010

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with a...

Por Ciuleanu, Tudor-Eliade, Ahmed, Samreen, Kim, Joo-Hang, Mezger, Jörg, Park, Keunchil, Thomas, Michael, Chen, Jihong, Poondru, Srinivasu, VanTornout, Jan M, Whitcomb, Debbie, Blackhall, Fiona
Publicado no Br J Cancer (2017)

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Por Jung, Minkyu, Kim, Se Hyun, Hong, Soojung, Kang, Young Ae, Kim, Se Kyu, Chang, Joon, Rha, Sun Young, Kim, Joo Hang, Kim, Dae Joon, Cho, Byoung Chul
Publicado em 2012

Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib o...

Por Jung, Minkyu, Kim, Se Hyun, Hong, Soojung, Kang, Young Ae, Kim, Se Kyu, Chang, Joon, Rha, Sun Young, Kim, Joo Hang, Kim, Dae Joon, Cho, Byoung Chul
Publicado em 2013

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non...

Por Kang, Jin Hyoung, Ahn, Myung-Ju, Kim, Dong-Wan, Cho, Eun Kyung, Kim, Joo-Hang, Shin, Sang Won, Wang, Xin, Kim, Jong Seok, Orlando, Mauro, Park, Keunchil
Publicado no Cancer Res Treat (2016)